dc.creator | Nyssen, Olga P. | es |
dc.creator | Vaira, Dino | es |
dc.creator | Saracino, Ilaria María | es |
dc.creator | Fiorini, Giulia | es |
dc.creator | Caldas, María | es |
dc.creator | Bujanda, Luis | es |
dc.creator | Pabón Carrasco, Manuel | es |
dc.creator | Gisbert, Javier P. | es |
dc.date.accessioned | 2022-12-01T16:33:34Z | |
dc.date.available | 2022-12-01T16:33:34Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Nyssen, O.P., Vaira, D., Saracino, I.M., Fiorini, G., Caldas, M., Bujanda, L.,...,Gisbert, J.P. (2022). Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). Journal of Clinical Medicine, 11 (6), 1658. https://doi.org/10.3390/jcm11061658. | |
dc.identifier.issn | 2077-0383 | es |
dc.identifier.uri | https://hdl.handle.net/11441/140051 | |
dc.description.abstract | Background: First-line Helicobacter pylori (H. pylori) treatments have been relatively well
evaluated; however, it remains necessary to identify the most effective rescue treatments. Our aim
was to assess the effectiveness and safety of H. pylori regimens containing rifabutin. METHODS:
International multicentre prospective non-interventional European Registry on H. pylori Management
(Hp-EuReg). Patients treated with rifabutin were registered in AEG-REDCap e-CRF from 2013 to
2021. Modified intention-to-treat and per-protocol analyses were performed. Data were subject to
quality control. Results: Overall, 500 patients included in the Hp-EuReg were treated with rifabutin
(mean age 52 years, 72% female, 63% with dyspepsia, 4% with peptic ulcer). Culture was performed
in 63% of cases: dual resistance (to both clarithromycin and metronidazole) was reported in 46% of
the cases, and triple resistance (to clarithromycin, metronidazole, and levofloxacin) in 39%. In 87% of cases rifabutin was utilised as part of a triple therapy together with amoxicillin and a proton-pump inhibitor, and in an additional 6% of the patients, bismuth was added to this triple regimen. Rifabutin
was mainly used in second-line (32%), third-line (25%), and fourth-line (27%) regimens, achieving
overall 78%, 80% and 66% effectiveness by modified intention-to-treat, respectively. Compliance
with treatment was 89%. At least one adverse event was registered in 26% of the patients (most
frequently nausea), and one serious adverse event (0.2%) was reported in one patient with leukope nia and thrombocytopenia with fever requiring hospitalisation. Conclusion: Rifabutin-containing
therapy represents an effective and safe strategy after one or even several failures of H. pylori
eradication treatment. | es |
dc.format | application/pdf | es |
dc.format.extent | 13 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | Journal of Clinical Medicine, 11 (6), 1658. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Helicobacter pylori | es |
dc.subject | H. pylori | es |
dc.subject | Rifabutin | es |
dc.subject | Treatment | es |
dc.subject | Eradication failure | es |
dc.subject | Culture | es |
dc.subject | Bismuth | es |
dc.subject | Rescue | es |
dc.subject | Hp-EuReg | es |
dc.title | Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg) | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Enfermería | es |
dc.relation.publisherversion | https://www.mdpi.com/2077-0383/11/6/1658 | es |
dc.identifier.doi | 10.3390/jcm11061658 | es |
dc.contributor.group | Universidad de Sevilla. CTS1054: Intervenciones y cuidados de la salud. Cruz Roja. | es |
dc.journaltitle | Journal of Clinical Medicine | es |
dc.publication.volumen | 11 | es |
dc.publication.issue | 6 | es |
dc.publication.initialPage | 1658 | es |